{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T19:40:26Z","timestamp":1779219626603,"version":"3.51.4"},"reference-count":56,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2023,4,7]],"date-time":"2023-04-07T00:00:00Z","timestamp":1680825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Despite several targeted antiviral drugs against SARS-CoV-2 currently being available, the application of type I interferons (IFNs) still deserves attention as an alternative antiviral strategy. This study aimed to assess the therapeutic effectiveness of IFN-\u03b1 in hospitalized patients with COVID-19-associated pneumonia. The prospective cohort study included 130 adult patients with coronavirus disease (COVID-19). A dose of 80,000 IU of IFN-\u03b12b was administered daily intranasally for 10 days. Adding IFN-\u03b12b to standard therapy reduces the length of the hospital stay by 3 days (p &lt; 0.001). The level of CT-diagnosed lung injuries was reduced from 35% to 15% (p = 0.011) and CT injuries decreased from 50% to 15% (p = 0.017) by discharge. In the group of patients receiving IFN-\u03b12b, the SpO2 index before and after treatment increased from 94 (92\u201396, Q1\u2013Q3) to 96 (96\u201398, Q1\u2013Q3) (p &lt; 0.001), while the percentage of patients with normal saturation increased (from 33.9% to 74.6%, p &lt; 0.05), but the level of SpO2 decreased in the low (from 52.5% to 16.9%) and very low (from 13.6% to 8.5%) categories. The addition of IFN-\u03b12b to standard therapy has a positive effect on the course of severe COVID-19.<\/jats:p>","DOI":"10.3390\/ijms24086887","type":"journal-article","created":{"date-parts":[[2023,4,7]],"date-time":"2023-04-07T04:08:03Z","timestamp":1680840483000},"page":"6887","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Therapeutic Effectiveness of Interferon-\u03b12b against COVID-19 with Community-Acquired Pneumonia: The Ukrainian Experience"],"prefix":"10.3390","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3141-4436","authenticated-orcid":false,"given":"Aleksandr","family":"Kamyshnyi","sequence":"first","affiliation":[{"name":"Department of Microbiology, Virology, and Immunology, I. Horbachevsky Ternopil National Medical University, Majdan Voli 1, 46001 Ternopil, Ukraine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7120-9253","authenticated-orcid":false,"given":"Halyna","family":"Koval","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology, Allergology and Endocrinology, Bukovinian State Medical University, Teatralnaya Square, 2, 58002 Chernivtsi, Ukraine"},{"name":"Department of Infectious Disease, Chernivtsi Regional Clinical Hospital, Holovna, 137, 58000 Chernivtsi, Ukraine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olha","family":"Kobevko","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease, Chernivtsi Regional Clinical Hospital, Holovna, 137, 58000 Chernivtsi, Ukraine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8735-0051","authenticated-orcid":false,"given":"Mykhailo","family":"Buchynskyi","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Virology, and Immunology, I. Horbachevsky Ternopil National Medical University, Majdan Voli 1, 46001 Ternopil, Ukraine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5088-3791","authenticated-orcid":false,"given":"Valentyn","family":"Oksenych","sequence":"additional","affiliation":[{"name":"Department of Clinical and Molecular Medicine (IKOM), Norwegian University of Science and Technology, 7028 Trondheim, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7716-6955","authenticated-orcid":false,"given":"Denis","family":"Kainov","sequence":"additional","affiliation":[{"name":"Department of Clinical and Molecular Medicine (IKOM), Norwegian University of Science and Technology, 7028 Trondheim, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katerina","family":"Lyubomirskaya","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Zaporizhzhia State Medical University, Maiakovskyi Avenue 26, 69000 Zaporizhzhia, Ukraine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4483-1856","authenticated-orcid":false,"given":"Iryna","family":"Kamyshna","sequence":"additional","affiliation":[{"name":"Department of Medical Rehabilitation, I. Horbachevsky Ternopil National Medical University, Majdan Voli 1, 46001 Ternopil, Ukraine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8924-3169","authenticated-orcid":false,"given":"Geert","family":"Potters","sequence":"additional","affiliation":[{"name":"Antwerp Maritime Academy, Noordkasteel Oost 6, 2030 Antwerp, Belgium"},{"name":"Department of Bioscience Engineering, University of Antwerp, Groenenborgerlaan 171, 2020 Antwerp, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2209-8681","authenticated-orcid":false,"given":"Olena","family":"Moshynets","sequence":"additional","affiliation":[{"name":"Biofilm Study Group, Department of Cell Regulatory Mechanisms, Institute of Molecular Biology and Genetics, National Academy of Sciences of Ukraine, 150 Zabolotnoho Str., 03680 Kyiv, Ukraine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,4,7]]},"reference":[{"key":"ref_1","unstructured":"(2023, February 15). WHO Director-General\u2019s Opening Remarks at the Media Briefing on COVID-19\u201411 March 2020. Available online: https:\/\/www.who.int\/director-general\/speeches\/detail\/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.spc.2020.12.029","article-title":"Global Economic Crisis, energy use, CO(2) emissions, and policy roadmap amid COVID-19","volume":"26","author":"Aktar","year":"2021","journal-title":"Sustain. Prod. Consum."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Jaro\u0144, A., Borucka, A., and Parczewski, R. (2022). Analysis of the impact of the COVID-19 pandemic on the value of CO2 emissions from electricity generation. Energies, 15.","DOI":"10.3390\/en15134514"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.bbrc.2004.11.128","article-title":"Ribavirin and interferon-beta synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines","volume":"326","author":"Morgenstern","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1136\/thorax.2003.012658","article-title":"Role of Lopinavir\/Ritonavir in the treatment of SARS: Initial virological and clinical findings","volume":"59","author":"Chu","year":"2004","journal-title":"Thorax"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and Chloroquine effectively inhibit the recently emerged novel coronavirus (2019-NCoV) in Vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.bbrc.2004.04.083","article-title":"HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus","volume":"318","author":"Yamamoto","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/j.jinf.2020.03.060","article-title":"Arbidol monotherapy is superior to lopinavir\/ritonavir in treating COVID-19","volume":"81","author":"Zhu","year":"2020","journal-title":"J. Infect."},{"key":"ref_9","first-page":"E002","article-title":"Potential antiviral therapeutics for 2019 Novel Coronavirus","volume":"43","author":"Li","year":"2020","journal-title":"Zhonghua Jie He He Hu Xi Za Zhi Zhonghua Jiehe He Huxi Zazhi Chin. J. Tuberc. Respir. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev-med-042420-113838","article-title":"SARS-CoV-2 neutralizing antibodies for COVID-19 prevention and treatment","volume":"73","author":"Li","year":"2022","journal-title":"Annu. Rev. Med."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Th\u00fcmmler, L., Lindemann, M., Horn, P.A., Lenz, V., Konik, M., G\u00e4ckler, A., Boss, K., Theodoropoulos, F., Besa, V., and Taube, C. (2023). Early treatment with monoclonal antibodies or convalescent plasma reduces mortality in non-vaccinated COVID-19 high-risk patients. Viruses, 15.","DOI":"10.3390\/v15010119"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.mayocp.2021.12.002","article-title":"Effectiveness of monoclonal antibodies in preventing severe COVID-19 with emergence of the delta variant","volume":"97","author":"Challener","year":"2022","journal-title":"Mayo Clin. Proc."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1080\/07853890.2022.2034936","article-title":"Efficacy and safety of three new oral antiviral treatment (Molnupiravir, Fluvoxamine and Paxlovid) for COVID-19: A Meta-Analysis","volume":"54","author":"Wen","year":"2022","journal-title":"Ann. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1056\/NEJMoa011232","article-title":"Treatment of acute hepatitis C with interferon Alfa-2b","volume":"345","author":"Jaeckel","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/nature04082","article-title":"mechanism of action of interferon and Ribavirin in treatment of hepatitis C","volume":"436","author":"Feld","year":"2005","journal-title":"Nature"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1038\/nm.3362","article-title":"Treatment with interferon-\u03b12b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques","volume":"19","author":"Falzarano","year":"2013","journal-title":"Nat. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"566","DOI":"10.3389\/fimmu.2019.00566","article-title":"Role of type I interferon (IFN) in the respiratory syncytial virus (RSV) immune response and disease severity","volume":"10","author":"Hijano","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e2203760119","DOI":"10.1073\/pnas.2203760119","article-title":"Interferon resistance of emerging SARS-CoV-2 variants","volume":"119","author":"Guo","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Ianevski, A., Yao, R., Zusinaite, E., Lello, L.S., Wang, S., Jo, E., Yang, J., Ravlo, E., Wang, W., and Lysvand, H. (2021). Synergistic interferon-Alpha-Based combinations for treatment of SARS-CoV-2 and other viral infections. Viruses, 13.","DOI":"10.21203\/rs.3.rs-189394\/v1"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Ianevski, A., Yao, R., Lysvand, H., Gr\u00f8deland, G., Legrand, N., Oksenych, V., Zusinaite, E., Tenson, T., Bj\u00f8r\u00e5s, M., and Kainov, D.E. (2021). Nafamostat-interferon-\u03b1 combination suppresses SARS-CoV-2 infection in vitro and in vivo by cooperatively targeting host TMPRSS2. Viruses, 13.","DOI":"10.1101\/2021.06.16.448653"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.jiac.2021.02.018","article-title":"A retrospective analysis of clinical efficacy of Ribavirin in adults hospitalized with severe COVID-19","volume":"27","author":"Gong","year":"2021","journal-title":"J. Infect. Chemother. Off. J. Japan Soc. Chemother."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1016\/j.jiph.2021.09.020","article-title":"The combined regimens of antiviral therapy might not be useful for the viral clearance of severe COVID-19 cases","volume":"14","author":"Li","year":"2021","journal-title":"J. Infect. Public Health"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Zhou, Q., MacArthur, M.R., He, X., Wei, X., Zarin, P., Hanna, B.S., Wang, Z.-H., Xiang, X., and Fish, E.N. (2020). interferon-\u03b12b treatment for COVID-19 is associated with improvements in lung abnormalities. Viruses, 13.","DOI":"10.3390\/v13010044"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s12985-021-01617-w","article-title":"Antiviral drugs Arbidol and interferon alpha-1b contribute to reducing the severity of COVID-19 patients: A retrospective cohort study","volume":"18","author":"Yin","year":"2021","journal-title":"Virol. J."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.ijid.2021.03.015","article-title":"Efficacy and safety of pegylated interferon alfa-2b in moderate COVID-19: A phase II, randomized, controlled, open-label study","volume":"105","author":"Pandit","year":"2021","journal-title":"Int. J. Infect. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.ijid.2021.08.044","article-title":"Efficacy and safety of pegylated interferon-\u03b12b in moderate COVID-19: A phase 3, randomized, comparator-controlled, open-label study","volume":"111","author":"Bhushan","year":"2021","journal-title":"Int. J. Infect. Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"250","DOI":"10.3389\/fimmu.2023.1069894","article-title":"efficacy of interferon alpha for the treatment of hospitalized patients with COVID-19: A meta-analysis","volume":"14","author":"Buchynskyi","year":"2023","journal-title":"Front. Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jcrc.2020.07.003","article-title":"The characteristics and outcomes of 681 severe cases with COVID-19 in China","volume":"60","author":"Chen","year":"2020","journal-title":"J. Crit. Care"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/bjh.16885","article-title":"Delayed-phase thrombocytopenia in patients with coronavirus disease 2019 (COVID-19)","volume":"190","author":"Chen","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1002\/hep4.1592","article-title":"Clinical features of patients with COVID-19 with nonalcoholic fatty liver disease","volume":"4","author":"Huang","year":"2020","journal-title":"Hepatol. Commun."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jaut.2018.08.003","article-title":"Interferon alpha: The key trigger of type 1 diabetes","volume":"94","author":"Lombardi","year":"2018","journal-title":"J. Autoimmun."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.chom.2020.05.008","article-title":"Type I and type III interferons-induction, signaling, evasion, and application to combat COVID-19","volume":"27","author":"Park","year":"2020","journal-title":"Cell Host Microbe"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1146\/annurev-virology-092818-015756","article-title":"Interferon-stimulated genes: What Do They All Do?","volume":"6","author":"Schoggins","year":"2019","journal-title":"Annu. Rev. Virol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"104811","DOI":"10.1016\/j.antiviral.2020.104811","article-title":"Antiviral activities of type I interferons to SARS-CoV-2 infection","volume":"179","author":"Mantlo","year":"2020","journal-title":"Antivir. Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"110954","DOI":"10.1016\/j.celrep.2022.110954","article-title":"Parsing the role of NSP1 in SARS-CoV-2 infection","volume":"39","author":"Fisher","year":"2022","journal-title":"Cell Rep."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Glanz, A., Chakravarty, S., Varghese, M., Kottapalli, A., Fan, S., Chakravarti, R., and Chattopadhyay, S. (2021). Transcriptional and non-transcriptional activation, posttranslational modifications, and antiviral functions of interferon regulatory factor 3 and viral antagonism by the SARS-coronavirus. Viruses, 29.","DOI":"10.3390\/v13040575"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.3389\/fimmu.2020.01061","article-title":"Interferon-\u03b12b treatment for COVID-19","volume":"11","author":"Zhou","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"920","DOI":"10.2174\/1568026621666210429083050","article-title":"The effect of recombinant human interferon alpha nasal drops to prevent COVID-19 pneumonia for medical staff in an epidemic area","volume":"21","author":"Meng","year":"2021","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1089\/jir.2020.0188","article-title":"Therapeutic effectiveness of interferon alpha 2b treatment for COVID-19 patient recovery","volume":"40","author":"Pereda","year":"2020","journal-title":"J. Interf. Cytokine Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.chom.2020.07.005","article-title":"retrospective multicenter cohort study shows early interferon therapy is associated with favorable clinical responses in COVID-19 patients","volume":"28","author":"Wang","year":"2020","journal-title":"Cell Host Microbe"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.chom.2020.04.017","article-title":"Heightened innate immune responses in the respiratory tract of COVID-19 patients","volume":"27","author":"Zhou","year":"2020","journal-title":"Cell Host Microbe"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Lopez, L., Sang, P.C., Tian, Y., and Sang, Y. (2020). dysregulated interferon response underlying severe COVID-19. Viruses, 12.","DOI":"10.3390\/v12121433"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e2446","DOI":"10.1038\/cddis.2016.350","article-title":"CD169(+) macrophages regulate PD-L1 expression via type I interferon and thereby prevent severe immunopathology after LCMV infection","volume":"7","author":"Shaabani","year":"2016","journal-title":"Cell Death Dis."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.cytogfr.2014.10.012","article-title":"Divergent Effects of Type-I Interferons on Regulatory T Cells","volume":"26","author":"Piconese","year":"2015","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.imlet.2019.01.013","article-title":"The role of type I interferons in CD4+ T cell differentiation","volume":"215","author":"Kuka","year":"2019","journal-title":"Immunol. Lett."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1126\/science.1235208","article-title":"Blockade of chronic type I interferon signaling to control persistent LCMV infection","volume":"340","author":"Wilson","year":"2013","journal-title":"Science"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Zhang, L., Yuan, S., Cheng, G., and Guo, B. (2011). Type I IFN promotes IL-10 production from T cells to suppress Th17 cells and Th17-associated autoimmune inflammation. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0028432"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2023184","article-title":"Repurposed antiviral drugs for COVID-19\u2014Interim WHO Solidarity Trial Results","volume":"384","author":"Pan","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Davoudi-Monfared, E., Rahmani, H., Khalili, H., Hajiabdolbaghi, M., Salehi, M., Abbasian, L., Kazemzadeh, H., and Yekaninejad, M.S. (2020). A randomized clinical trial of the efficacy and safety of interferon \u03b2-1a in treatment of severe COVID-19. Antimicrob. Agents Chemother., 64.","DOI":"10.1128\/AAC.01061-20"},{"key":"ref_50","first-page":"47","article-title":"JAK-inhibitor and type i interferon ability to produce favorable clinical outcomes in COVID-19 patients: A systematic review and meta-analysis","volume":"21","author":"Walz","year":"2020","journal-title":"Res. Sq."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"5277","DOI":"10.1002\/jmv.27072","article-title":"interferon-alpha position in combating with COVID-19: A systematic review","volume":"93","author":"Nakhlband","year":"2021","journal-title":"J. Med. Virol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.cytogfr.2022.01.001","article-title":"current utilization of interferon alpha for the treatment of coronavirus disease 2019: A comprehensive review","volume":"63","author":"Lu","year":"2022","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.cell.2020.04.026","article-title":"imbalanced host response to SARS-CoV-2 drives development of COVID-19","volume":"181","author":"Liu","year":"2020","journal-title":"Cell"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1126\/science.abc6027","article-title":"Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients","volume":"369","author":"Hadjadj","year":"2020","journal-title":"Science"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1038\/s41591-020-0944-y","article-title":"A single-cell atlas of the peripheral immune response to severe COVID-19","volume":"26","author":"Wilk","year":"2020","journal-title":"Nat. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1126\/sciimmunol.abd1554","article-title":"Immunophenotyping of COVID-19 and influenza highlights the role of type I interferons in development of severe COVID-19","volume":"5","author":"Lee","year":"2020","journal-title":"Sci. Immunol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/8\/6887\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:11:46Z","timestamp":1760123506000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/8\/6887"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,7]]},"references-count":56,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,4]]}},"alternative-id":["ijms24086887"],"URL":"https:\/\/doi.org\/10.3390\/ijms24086887","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,7]]}}}